Ryosuke Fujii
Senior Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Background Although utility of composite trait‐specific polygenic risk score (multi‐trait PRS) has been examined among European ancestries, few studies investigated among East Asians and incorporated modifiable risk factors. We examined the associations of multi‐trait PRS for cardiometabolic factors with cardiovascular disease mortality by integrating nongenetic determinants. Methods A total of 14 086 Japanese participants (mean age, 55±9; 55.8% women) of the J‐MICC (Japan Multi‐Institutional Collaborative Cohort) study were analyzed in this study. We calculated 6 PRSs for cardiometabolic traits (systolic blood pressure, body mass index, triglycerides, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, and hemoglobin A1c). Based on these PRSs, we developed multi‐trait PRS and considered as a primary exposure. Three nongenetic factors (smoking, alcohol drinking, and educational attainment) from the self‐reported questionnaire were also examined. Results During a median 12.1‐year follow‐up period, a total of 472 all‐cause and 79 cardiovascular disease mortality cases were documented. Compared with 0% to 90% of multi‐trait PRSs, an adjusted hazard ratio (HR) among the top 10% of multi‐trait PRSs was 1.32 (95% CI, 1.00–1.73) for all‐cause death and 2.63 (95% CI, 1.48–4.67) for cardiovascular disease death. Incorporation of educational attainment with multi‐trait PRSs showed null associations in those who went beyond high school (HR, 2.07 [95% CI, 0.44–9.66]) even in the top 10% of multi‐trait PRS. Conclusions Our analysis combining both genetic and nongenetic determinants highlighted that lifestyle factors and educational attainment can slightly reduce an individual's composite genetic risk for cardiovascular disease death.
Year:
2025
Background: Current evidence suggests an increased risk for cancer mortality in those with low aryl hydrocarbon receptor repressor (AHRR) DNA methylation (DNAm) levels. Therefore, AHRR DNAm could identify a more “fragile” group at risk for cancer mortality than questionnaire-based evaluations. Given this, the aim was to identify “fragile” groups at risk of cancer mortality by integrating questionnaire-based smoking indices and leukocyte AHRR DNAm levels in the Japanese population. Methods: The target population was 795 participants without a clinical history who underwent a health checkup in 1990. They were followed for up to 30 years for mortality. The AHRR DNAm levels in leukocytes were measured by the pyrosequencing method. HRs for cancer mortality were calculated using a Cox proportional hazards model. Results: Significantly higher HRs for all-cancer mortality were observed in low AHRR DNAm groups regardless of smoking intensity [pack-years <20: 3.69 (1.46–9.37); pack-years ≥20: 2.13 (1.11–4.09)]. Compared with current smokers, significantly lower HRs for all-cancer mortality were observed in the group with high AHRR DNAm regardless of years since quitting [YSQ ≤10: 0.13 (0.02–0.96); YSQ >10: 0.28 (0.08–0.98)]. Even for YSQ greater than 10, there was no significant mortality risk reduction in the low AHRR DNAm group. Conclusions: The population with low AHRR DNAm levels had a higher risk of cancer mortality even with low smoking exposure. Furthermore, no significant risk reduction was observed in former smokers with low AHRR DNAm levels. Impact: AHRR DNAm levels in leukocytes may help identify groups at risk for cancer mortality overlooked by questionnaire-based smoking indices.
Year:
2025
Purpose The present study aimed to clarify associations between coffee intake and kidney function with consideration of the effect modifications from coffee intake-related genetic polymorphisms. Methods This cross-sectional study included 7,468 Japanese participants 35–69 years old (3,953 women: 52.9%) from the baseline survey of the Japan Multi-Institutional Collaborative Cohort study. Coffee intake was estimated with a self-administered questionnaire. Three coffee intake-related single nucleotide polymorphisms (in AHR [rs4410790], HECTD4 [rs2074356], and CYP1A2 [rs762551]) were selected with reference to previous studies. Estimated glomerular filtration rate (eGFR [ml/min/1.73 m 2 ]) and CKD (defined as eGFR < 60 ml/min/1.73 m 2 ) were determined. Results In participants with a slow metabolizing genotype of rs4410790, eGFR with higher coffee intake was 1.64 ml/min/1.73 m 2 (95% CI 0.29–2.98) lower than with low coffee intake. For a frequent coffee consumer genotype of rs2074356, eGFR in participants with moderate coffee intake was higher than with low coffee intake. For heterozygous-type rs762551, coffee intake was associated with a lower prevalence of CKD (OR: 0.53, 95% CI 0.33–0.83). Moreover, with the frequent coffee consumer genotype of rs2074356, higher coffee intake was associated with a lower prevalence of CKD (OR: 0.27, 95% CI 0.08–0.78). Conclusion Associations of coffee intake with kidney function and CKD may differ across coffee intake-related polymorphisms in Japanese adults. These findings suggest that attention should be paid to heterogeneous associations between coffee intake and kidney function according to genetic polymorphisms. Further longitudinal studies are expected to address causal questions of these associations.
Year:
2025
Background: Current evidence suggests an increased risk for cancer mortality in those with low aryl hydrocarbon receptor repressor ( AHRR ) DNA methylation (DNAm) levels. Therefore, AHRR DNAm could identify a more “fragile” group at risk for cancer mortality than questionnaire-based evaluations. Given this, the aim was to identify “fragile” groups at risk of cancer mortality by integrating questionnaire-based smoking indices and leukocyte AHRR DNAm levels in the Japanese population. Methods: The target population was 795 participants without a clinical history who underwent a health checkup in 1990. They were followed for up to 30 years for mortality. The AHRR DNAm levels in leukocytes were measured by the pyrosequencing method. HRs for cancer mortality were calculated using a Cox proportional hazards model. Results: Significantly higher HRs for all-cancer mortality were observed in low AHRR DNAm groups regardless of smoking intensity [pack-years AHRR DNAm regardless of years since quitting [YSQ ≤10: 0.13 (0.02–0.96); YSQ >10: 0.28 (0.08–0.98)]. Even for YSQ greater than 10, there was no significant mortality risk reduction in the low AHRR DNAm group. Conclusions: The population with low AHRR DNAm levels had a higher risk of cancer mortality even with low smoking exposure. Furthermore, no significant risk reduction was observed in former smokers with low AHRR DNAm levels. Impact: AHRR DNAm levels in leukocytes may help identify groups at risk for cancer mortality overlooked by questionnaire-based smoking indices.
Year:
2025
Summary Genome-wide association studies (GWAS) generated thousands of loci associated with complex traits and diseases. However, to characterize of the pleiotropic, molecular and population genetic bounds of uncovered loci, investigations are conducted, that remain conceptually and practically separated. Also in the best case, such investigations proceed by one locus at a time. To address these limitations, we introduce an efficient and reproducible Snakemake pipeline for executing haplotype-based association analysis on GWAS-identified genetic loci, which is especially helpful in samples enriched with molecular omics data. Haplomics takes as input the genetic coordinates of each locus along with all available clinical and molecular phenotypes, the necessary covariates, and VCF genotype files, to reconstruct haplotypes and test them for associations with the phenotypes. The reconstructed haplotypes, the annotation of included variants, and association results are graphically displayed in an HTML report. We tested Haplomics in population-based study sample encompassing 391 traits, including 72 clinical markers, 171 serum metabolites, 148 plasma protein concentrations, and whole-exome sequencing (WES) imputed genotypes. We estimated WES-based haplotypes at 11 kidney function genetic loci from a GWAS and conducted association analyses throughout, identifying 19 significant associations after multiple testing correction. Haplomics is a scalable, easy-to-use and fast haplotype reconstruction and association pipeline that makes it possible to jointly conduct molecular and population-genetic characterization of multiple GWAS loci in unified analysis framework. Availability and implementation Haplomics is freely available on GitHub at https://github.com/dariushghasemi/haplomics .
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (21)
Kyuto Sonehara
Associate Professor
University of Tsukuba
Koji Ohashi
Professor
Fujita Health University
Cristian Pattaro
Researcher
Eurac Research
Giovanni Malerba
Associate Professor
University of Verona
Hiroya Yamada
Fujita Health University
Essi Hantikainen
Senior Researcher
Eurac Research
Peter P Pramstaller
Head of Institute
Eurac Research
Maria Elisabetta Zanolin
University of Verona
Masashi Ishizu-Jo
Assistant Professor
Tokushima University
Markus Ralser
Senior Group Leader
The Francis Crick Institute
Keisuke Maeda
Senior Assistant Professor
Fujita Health University
ryuta baba
Hiroshima University
Koji Suzuki
Professor
Fujita Health University
Giovanni Gambaro
Full Professor/Director
University of Verona
Hiroaki Ikezaki
Associate Professor
Kyushu University Graduate School of Medical Sciences
Vanessa Garcia Larsen
Associate Professor
Johns Hopkins University Bloomberg School of Public Health
Mako Nagayoshi
Lecturer
Nagoya University Graduate School of Medicine
Shuntaro Sato
Nagasaki University
Takeshi Watanabe
Assistant Professor
Tokushima University
Andres Cardenas
Assistant Professor
Stanford University
Roberto Melotti
Senior Researcher
Eurac Research
Make your next move.
Prepare your application
Review drafts before you send them.